HSDT
Solana CompanyNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
136.28
P/S
12.46
EV/EBITDA
-1.68
DCF Value
$-11.95
FCF Yield
-22.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.7%
Operating Margin
-4052.5%
Net Margin
-679.6%
ROE
113.0%
ROA
-13.5%
ROIC
-81.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.2M | $325.5M | $36.45 |
| FY 2025 | $6.0M | $-40.9M | $-1.85 |
| Q3 2025 | $697.0K | $-352.8M | $-32.89 |
| Q2 2025 | $43.0K | $-9.8M | $-3.99 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.91
Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.